Screening in adrenal tumorsCorssmit, Eleonora P.M.a,b; Dekkers, Olaf M.a,b,cCurrent Opinion in Oncology: May 2019 - Volume 31 - Issue 3 - p 243–246 doi: 10.1097/CCO.0000000000000528 ENDOCRINE TUMORS: Edited by Christiane Jungels Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Adrenal tumors are mostly encountered as incidentalomas in patients undergoing imaging not performed for suspected adrenal disease; although the majority are benign and nonfunctioning, malignant tumors and functioning tumors need to be excluded. The purpose of this review is to highlight recent advances in the evaluation of adrenal tumors. Recent findings As a consequence of increased use of technologically improved imaging techniques, the detection of adrenal incidentalomas has continued to increase. The vast majority of adrenal tumors are adrenocortical adenomas. To discriminate malignant from benign tumors and to identify clinically relevant functioning tumors, necessitating therapeutic intervention, adrenal tumors are best evaluated with unenhanced computed tomography (CT) attenuation and 1 mg dexamethasone overnight suppression test. An unenhanced CT attenuation value of 10 Hounsfield units or less excludes adrenocortical carcinoma and pheochromocytoma. Testing for hyperaldosteronism should be performed in hypertensive and/or hypokalemic patients, sex hormones, and steroid precursors in patients with clinical features suggestive of adrenocortical carcinoma. In patients with active extraadrenal malignancy and a single adrenal lesion without suspicion for metastasis elsewhere, CT-guided biopsy can be considered to rule out metastatic disease. Summary All patients with an adrenal tumor and without a prior history of cancer should be initially evaluated by unenhanced CT attenuation and 1 mg overnight dexamethasone suppression test, and additional hormone testing when indicated. aDepartment of Medicine, Division of Endocrinology bCenter of Endocrine Tumors Leiden (CETL), Department of Endocrinology cDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands Correspondence to Eleonora P.M. Corssmit, MD, PhD, Department of Medicine, Division of Endocrinology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Tel: +31715263082; fax: +31715248136; e-mail: E.P.M.van_der_Kleij-Corssmit@lumc.nl Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.